GlassScriptPhysician profile
Aaron C Rippelmeyer
NPI 1477911857
$3,154.14
in general payments reported to CMS, 2019-2025
27 companies · $631 in 2025
The $631 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $446 · 2023: $1,027 · 2024: $511 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.73 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $683.87 | 2021-2025 | Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $538.24 | 2021-2025 | |
| Amgen INC. | $238.70 | 2021-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $206.64 | 2022-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $162.65 | 2022-2025 | Watchman Access System, General - Crm_crm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.82 | 2021-2023 | Jardiance |
| Abiomed | $142.19 | 2023-2024 | Impella |
| Janssen Pharmaceuticals, INC | $140.74 | 2021-2024 | Xarelto |
| Pfizer INC. | $137.74 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.17 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.22 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $93.39 | 2022-2024 | Verquvo, Winrevair |
| Kiniksa Pharmaceuticals, LTD. | $64.48 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $49.92 | 2023-2025 | Farxiga |
| Csl Behring | $47.95 | 2023 | Kcentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35.98 | 2022-2025 | Micra |
| Novo Nordisk INC | $34.19 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $27.67 | 2025 | Inspire |
| Biosense Webster, INC. | $24.30 | 2025 | |
| Scpharmaceuticals INC. | $22.80 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $21.64 | 2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $20.34 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $15.18 | 2023 | Inpefa |
| Cvrx, INC. | $14.81 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $13.74 | 2025 | Nexletol |
| Amarin Pharma, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Rippelmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.